Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Protein and Peptide Letters
  4. Volume 32, Issue 2
  5. Article
Volume 32, Issue 2
  • ISSN: 0929-8665
  • E-ISSN: 1875-5305

Abstract

Background

The role of Zona pellucida glycoprotein 3 (ZP3) is unclear in pancreatic adenocarcinoma (PAAD).

Objective

This study aimed to explore the role of ZP3 in PAAD.

Methods

A comparative analysis of ZP3 gene expression was performed to discern differences between various types of cancer and PAAD, leveraging data sourced from The Cancer Genome Atlas (TCGA). This study aimed to assess the role of ZP3 as a potential diagnostic marker for PAAD. The relationship between ZP3 levels and clinical characteristics, as well as patient outcomes, was scrutinized. Additionally, genomic enrichment analysis was carried out to uncover the underlying regulatory mechanisms associated with ZP3. The study further delved into the association of ZP3 with immune system interactions, checkpoint gene expression, Tumor Mutational Burden (TMB), microsatellite instability (MSI), and tumor stemness index (mRNAsi). The aberrant expression patterns of ZP3 in PAAD cell cultures were confirmed through the application of quantitative reverse transcription PCR (qRT-PCR) techniques.

Results

ZP3 exhibited aberrant expression in both pan-cancer and PAAD. A significant correlation was observed between increased levels of ZP3 expression in PAAD patients and histologic grade ( 0.026). Elevated ZP3 expression in PAAD was found to be significantly associated with poorer overall survival ( 0.003), progression-free survival ( 0.012), and disease-specific survival ( 0.002). In PAAD, the level of ZP3 gene expression was statistically significant ( 0.001) and recognized as a key determinant of patient prognosis. ZP3 exhibited associations with various biological pathways, including primary immunodeficiency, oxidative phosphorylation, and other pathways. ZP3 expression demonstrated correlations with immune infiltration, immune checkpoint genes, TMB, MSI, and mRNAsi in PAAD. Moreover, a pronounced negative correlation was detected between ZP3 expression levels and the therapeutic effectiveness of various medications, including selumetinib, bleomycin, FH535, docetaxel, and tanespimycin, within the context of PAAD. Elevated levels of ZP3 were consistently observed in cell line models of PAAD.

Conclusion

ZP3 has the potential to serve as a prognostic biomarker and therapeutic target for patients with PAAD.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ppl/10.2174/0109298665350171241204153202
2025-01-08
2025-06-23

  • From This Site

    /content/journals/ppl/10.2174/0109298665350171241204153202
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. McGuiganA. KellyP. TurkingtonR.C. JonesC. ColemanH.G. McCainR.S. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes.World J. Gastroenterol.201824434846486110.3748/wjg.v24.i43.484630487695
     [Google Scholar]
  2. MizrahiJ.D. SuranaR. ValleJ.W. ShroffR.T. Pancreatic cancer.Lancet2020395102422008202010.1016/S0140‑6736(20)30974‑032593337
     [Google Scholar]
  3. HessmannE. BuchholzS.M. DemirI.E. SinghS.K. GressT.M. EllenriederV. NeesseA. Microenvironmental determinants of pancreatic cancer.Physiol. Rev.202010041707175110.1152/physrev.00042.201932297835
     [Google Scholar]
  4. QianY. GongY. FanZ. LuoG. HuangQ. DengS. ChengH. JinK. NiQ. YuX. LiuC. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.J. Hematol. Oncol.202013113010.1186/s13045‑020‑00958‑333008426
     [Google Scholar]
  5. BansalP. ChakrabartiK. GuptaS.K. Functional activity of human ZP3 primary sperm receptor resides toward its C-terminus.Biol. Reprod.200981171510.1095/biolreprod.108.07471619246320
     [Google Scholar]
  6. WassarmanP.M. LitscherE.S. Egg’s ZP3 structure speaks volumes.Cell2010143333733810.1016/j.cell.2010.10.01321029855
     [Google Scholar]
  7. LefièvreL. ConnerS.J. SalpekarA. OlufowobiO. AshtonP. PavlovicB. LentonW. AfnanM. BrewisI.A. MonkM. HughesD.C. BarrattC.L. Four zona pellucida glycoproteins are expressed in the human.Hum. Reprod.20041971580158610.1093/humrep/deh30115142998
     [Google Scholar]
  8. ChiuP.C.N. WongB.S.T. ChungM.K. LamK.K.W. PangR.T.K. LeeK.F. SumitroS.B. GuptaS.K. YeungW.S.B. Effects of native human zona pellucida glycoproteins 3 and 4 on acrosome reaction and zona pellucida binding of human spermatozoa.Biol. Reprod.200879586987710.1095/biolreprod.108.06934418667750
     [Google Scholar]
  9. GookD.A. EdgarD.H. BorgJ. MarticM. Detection of zona pellucida proteins during human folliculogenesis.Hum. Reprod.200723239440210.1093/humrep/dem37318033806
     [Google Scholar]
  10. BiY. JinS. TangG. PanD. SongX. ZhuX. TanS. Prognostic significance of ZP3 in hepatocellular carcinoma.Comb. Chem. High Throughput Screen.20232691729173610.2174/138620732566622101011260136221877
     [Google Scholar]
  11. RahmanN.A. BenninkH.J.T.C. ChruscielM. SharpV. ZimmermanY. DinaR. LiX. EllonenA. Rivero-MüllerA. DilworthS. Ghaem-MaghamiS. VainioO. HuhtaniemiI. A novel treatment strategy for ovarian cancer based on immunization against zona pellucida protein (ZP) 3.FASEB J.201226132433310.1096/fj.11‑19246821974931
     [Google Scholar]
  12. AhluwaliaP. AhluwaliaM. MondalA.K. SahajpalN. KotaV. RojianiM.V. RojianiA.M. KolheR. Prognostic and therapeutic implications of extracellular matrix associated gene signature in renal clear cell carcinoma.Sci. Rep.2021111756110.1038/s41598‑021‑86888‑733828127
     [Google Scholar]
  13. YangD. LiuM. JiangJ. LuoY. WangY. ChenH. LiD. WangD. YangZ. ChenH. Comprehensive analysis of DMRT3 as a potential biomarker associated with the immune infiltration in a pan-cancer analysis and validation in lung adenocarcinoma.Cancers (Basel)20221424622010.3390/cancers1424622036551704
     [Google Scholar]
  14. HanQ. CuiZ. WangQ. PangF. LiD. WangD. Upregulation of OTX2-AS1 is associated with immune infiltration and predicts prognosis of gastric cancer.Technol. Cancer Res. Treat.2023221533033823115409110.1177/1533033823115409136740995
     [Google Scholar]
  15. LiangW. LuY. PanX. ZengY. ZhengW. LiY. NieY. LiD. WangD. Decreased expression of a novel lncRNA FAM181A-AS1 is associated with poor prognosis and immune infiltration in lung adenocarcinoma.Pharm. Genomics Pers. Med.20221598599810.2147/PGPM.S38490136482943
     [Google Scholar]
  16. WangJ. DaiW. ZhangM. GATA3 positively regulates PAR1 to facilitate in vitro disease progression and decrease cisplatin sensitivity in neuroblastoma via inhibiting the hippo pathway.Anticancer Drugs2023341577210.1097/CAD.000000000000134135946556
     [Google Scholar]
  17. PanH. LiuQ. ZhangF. WangX. WangS. ShiX. High STK40 expression as an independent prognostic biomarker and correlated with immune infiltrates in low-grade gliomas.Int. J. Gen. Med.2021146389640010.2147/IJGM.S33582134675607
     [Google Scholar]
  18. LinZ. HuangW. YiY. LiD. XieZ. LiZ. YeM. LncRNA ADAMTS9-AS2 is a prognostic biomarker and correlated with immune infiltrates in lung adenocarcinoma.Int. J. Gen. Med.2021148541855510.2147/IJGM.S34068334849000
     [Google Scholar]
  19. RuiS. WangD. HuangY. XuJ. ZhouH. ZhangH. Prognostic value of SLC4A4 and its correlation with the microsatellite instability in colorectal cancer.Front. Oncol.202313117912010.3389/fonc.2023.117912037152025
     [Google Scholar]
  20. HuangH. XuQ. ZhangY. ZhouY. MaK. LuoY. miR-628-5p is a potential novel prognosis biomarker, associated with immune infiltration in bladder urothelial carcinoma.Curr. Pharm. Des.202329312477248810.2174/011381612825462123101706292337916623
     [Google Scholar]
  21. YiW. ShenH. SunD. XuY. FengY. LiD. WangC. Low expression of long noncoding RNA SLC26A4 antisense RNA 1 is an independent prognostic biomarker and correlate of immune infiltrates in breast cancer.Med. Sci. Monit.202127e93452234880202
     [Google Scholar]
  22. ChenJ. TangH. LiT. JiangK. ZhongH. WuY. HeJ. LiD. LiM. CaiX. Comprehensive analysis of the expression, prognosis, and biological significance of OVOLs in breast cancer.Int. J. Gen. Med.2021143951396010.2147/IJGM.S32640234345183
     [Google Scholar]
  23. RenZ. ZhangX. HanJ. Expression and prognostic significance of ferroptosis-related proteins SLC7A11 and GPX4 in renal cell carcinoma.Protein Pept. Lett.2023301086887610.2174/010929866525570423092006325437807410
     [Google Scholar]
  24. RenS. ChenM. ChenY. DingK. NRSN2 is a prognostic biomarker in gastric cancer and facilitates the growth and migration of gastric cancer cells.Protein Pept. Lett.202330542743810.2174/092986653066623031416023436918782
     [Google Scholar]
  25. WangM. LiW. HanG. BaiX. XieJ. MicroRNA-605-3p inhibited the growth and chemoresistance of osteosarcoma cells via negatively modulating RAF1.Protein Pept. Lett.202431755956810.2174/010929866531465824071205120639076089
     [Google Scholar]
  26. ChenB. LuX. ZhouQ. ChenQ. ZhuS. LiG. LiuH. PAXIP1-AS1 is associated with immune infiltration and predicts poor prognosis in ovarian cancer.PLoS One2023188e029003110.1371/journal.pone.029003137582104
     [Google Scholar]
  27. LiuJ. LichtenbergT. HoadleyK.A. PoissonL.M. LazarA.J. CherniackA.D. KovatichA.J. BenzC.C. LevineD.A. LeeA.V. OmbergL. WolfD.M. ShriverC.D. ThorssonV. HuH. Caesar-JohnsonS.J. DemchokJ.A. FelauI. KasapiM. FergusonM.L. HutterC.M. SofiaH.J. TarnuzzerR. WangZ. YangL. ZenklusenJ.C. ZhangJ.J. ChudamaniS. LiuJ. LollaL. NareshR. PihlT. SunQ. WanY. WuY. ChoJ. DeFreitasT. FrazerS. GehlenborgN. GetzG. HeimanD.I. KimJ. LawrenceM.S. LinP. MeierS. NobleM.S. SaksenaG. VoetD. ZhangH. BernardB. ChambweN. DhankaniV. KnijnenburgT. KramerR. LeinonenK. LiuY. MillerM. ReynoldsS. ShmulevichI. ThorssonV. ZhangW. AkbaniR. BroomB.M. HegdeA.M. JuZ. KanchiR.S. KorkutA. LiJ. LiangH. LingS. LiuW. LuY. MillsG.B. NgK-S. RaoA. RyanM. WangJ. WeinsteinJ.N. ZhangJ. AbeshouseA. ArmeniaJ. ChakravartyD. ChatilaW.K. de BruijnI. GaoJ. GrossB.E. HeinsZ.J. KundraR. LaK. LadanyiM. LunaA. NissanM.G. OchoaA. PhillipsS.M. ReznikE. Sanchez-VegaF. SanderC. SchultzN. SheridanR. SumerS.O. SunY. TaylorB.S. WangJ. ZhangH. AnurP. PetoM. SpellmanP. BenzC. StuartJ.M. WongC.K. YauC. HayesD.N. ParkerJ.S. WilkersonM.D. AllyA. BalasundaramM. BowlbyR. BrooksD. CarlsenR. ChuahE. DhallaN. HoltR. JonesS.J.M. KasaianK. LeeD. MaY. MarraM.A. MayoM. MooreR.A. MungallA.J. MungallK. RobertsonA.G. SadeghiS. ScheinJ.E. SipahimalaniP. TamA. ThiessenN. TseK. WongT. BergerA.C. BeroukhimR. CherniackA.D. CibulskisC. GabrielS.B. GaoG.F. HaG. MeyersonM. SchumacherS.E. ShihJ. KucherlapatiM.H. KucherlapatiR.S. BaylinS. CopeL. DanilovaL. BootwallaM.S. LaiP.H. MaglinteD.T. Van Den BergD.J. WeisenbergerD.J. AumanJ.T. BaluS. BodenheimerT. FanC. HoadleyK.A. HoyleA.P. JefferysS.R. JonesC.D. MengS. MieczkowskiP.A. MoseL.E. PerouA.H. PerouC.M. RoachJ. ShiY. SimonsJ.V. SkellyT. SolowayM.G. TanD. VeluvoluU. FanH. HinoueT. LairdP.W. ShenH. ZhouW. BellairM. ChangK. CovingtonK. CreightonC.J. DinhH. DoddapaneniH.V. DonehowerL.A. DrummondJ. GibbsR.A. GlennR. HaleW. HanY. HuJ. KorchinaV. LeeS. LewisL. LiW. LiuX. MorganM. MortonD. MuznyD. SantibanezJ. ShethM. ShinbroE. WangL. WangM. WheelerD.A. XiL. ZhaoF. HessJ. AppelbaumE.L. BaileyM. CordesM.G. DingL. FronickC.C. FultonL.A. FultonR.S. KandothC. MardisE.R. McLellanM.D. MillerC.A. SchmidtH.K. WilsonR.K. CrainD. CurleyE. GardnerJ. LauK. MalleryD. MorrisS. PaulauskisJ. PennyR. SheltonC. SheltonT. ShermanM. ThompsonE. YenaP. BowenJ. Gastier-FosterJ.M. GerkenM. LeraasK.M. LichtenbergT.M. RamirezN.C. WiseL. ZmudaE. CorcoranN. CostelloT. HovensC. CarvalhoA.L. de CarvalhoA.C. FregnaniJ.H. Longatto-FilhoA. ReisR.M. Scapulatempo-NetoC. SilveiraH.C.S. VidalD.O. BurnetteA. EschbacherJ. HermesB. NossA. SinghR. AndersonM.L. CastroP.D. IttmannM. HuntsmanD. KohlB. LeX. ThorpR. AndryC. DuffyE.R. LyadovV. PaklinaO. SetdikovaG. ShabuninA. TavobilovM. McPhersonC. WarnickR. BerkowitzR. CramerD. FeltmateC. HorowitzN. KibelA. MutoM. RautC.P. MalykhA. Barnholtz-SloanJ.S. BarrettW. DevineK. FulopJ. OstromQ.T. ShimmelK. WolinskyY. SloanA.E. De RoseA. GiulianteF. GoodmanM. KarlanB.Y. HagedornC.H. EckmanJ. HarrJ. MyersJ. TuckerK. ZachL.A. DeyarminB. HuH. KvecherL. LarsonC. MuralR.J. SomiariS. VichaA. ZelinkaT. BennettJ. IacoccaM. RabenoB. SwansonP. LatourM. LacombeL. TêtuB. BergeronA. McGrawM. StaugaitisS.M. ChabotJ. HibshooshH. SepulvedaA. SuT. WangT. PotapovaO. VoroninaO. DesjardinsL. MarianiO. Roman-RomanS. SastreX. SternM-H. ChengF. SignorettiS. BerchuckA. BignerD. LippE. MarksJ. McCallS. McLendonR. SecordA. SharpA. BeheraM. BratD.J. ChenA. DelmanK. ForceS. KhuriF. MaglioccaK. MaithelS. OlsonJ.J. OwonikokoT. PickensA. RamalingamS. ShinD.M. SicaG. Van MeirE.G. ZhangH. EijckenboomW. GillisA. KorpershoekE. LooijengaL. OosterhuisW. StoopH. van KesselK.E. ZwarthoffE.C. CalatozzoloC. CuppiniL. CuzzubboS. DiMecoF. FinocchiaroG. MatteiL. PerinA. PolloB. ChenC. HouckJ. LohavanichbutrP. HartmannA. StoehrC. StoehrR. TaubertH. WachS. WullichB. KyclerW. MurawaD. WiznerowiczM. ChungK. EdenfieldW.J. MartinJ. BaudinE. BubleyG. BuenoR. De RienzoA. RichardsW.G. KalkanisS. MikkelsenT. NoushmehrH. ScarpaceL. GirardN. AymerichM. CampoE. GinéE. GuillermoA.L. Van BangN. HanhP.T. PhuB.D. TangY. ColmanH. EvasonK. DottinoP.R. MartignettiJ.A. GabraH. JuhlH. AkeredoluT. StepaS. HoonD. AhnK. KangK.J. BeuschleinF. BreggiaA. BirrerM. BellD. BoradM. BryceA.H. CastleE. ChandanV. ChevilleJ. CoplandJ.A. FarnellM. FlotteT. GiamaN. HoT. KendrickM. KocherJ-P. KoppK. MoserC. NagorneyD. O’BrienD. O’NeillB.P. PatelT. PetersenG. QueF. RiveraM. RobertsL. SmallridgeR. SmyrkT. StantonM. ThompsonR.H. TorbensonM. YangJ.D. ZhangL. BrimoF. AjaniJ.A. Angulo GonzalezA.M. BehrensC. BondarukJ. BroaddusR. CzerniakB. EsmaeliB. FujimotoJ. GershenwaldJ. GuoC. LazarA.J. LogothetisC. Meric-BernstamF. MoranC. RamondettaL. RiceD. SoodA. TamboliP. ThompsonT. TroncosoP. TsaoA. WistubaI. CarterC. HayduL. HerseyP. JakrotV. KakavandH. KeffordR. LeeK. LongG. MannG. QuinnM. SawR. ScolyerR. ShannonK. SpillaneA. StretchJ. SynottM. ThompsonJ. WilmottJ. Al-AhmadieH. ChanT.A. GhosseinR. GopalanA. LevineD.A. ReuterV. SingerS. SinghB. TienN.V. BroudyT. MirsaidiC. NairP. DrwiegaP. MillerJ. SmithJ. ZarenH. ParkJ-W. HungN.P. KebebewE. LinehanW.M. MetwalliA.R. PacakK. PintoP.A. SchiffmanM. SchmidtL.S. VockeC.D. WentzensenN. WorrellR. YangH. MoncrieffM. GoparajuC. MelamedJ. PassH. BotnariucN. CaramanI. CernatM. ChemencedjiI. ClipcaA. DorucS. GorincioiG. MuraS. PirtacM. StanculI. TcaciucD. AlbertM. AlexopoulouI. ArnaoutA. BartlettJ. EngelJ. GilbertS. ParfittJ. SekhonH. ThomasG. RasslD.M. RintoulR.C. BifulcoC. TamakawaR. UrbaW. HaywardN. TimmersH. AntenucciA. FaccioloF. GraziG. MarinoM. MerolaR. de KrijgerR. Gimenez-RoqueploA-P. PichéA. ChevalierS. McKercherG. BirsoyK. BarnettG. BrewerC. FarverC. NaskaT. PennellN.A. RaymondD. SchileroC. SmolenskiK. WilliamsF. MorrisonC. BorgiaJ.A. LiptayM.J. PoolM. SederC.W. JunkerK. OmbergL. DinkinM. ManikhasG. AlvaroD. BragazziM.C. CardinaleV. CarpinoG. GaudioE. CheslaD. CottinghamS. DubinaM. MoiseenkoF. DhanasekaranR. BeckerK-F. JanssenK-P. Slotta-HuspeninaJ. Abdel-RahmanM.H. AzizD. BellS. CebullaC.M. DavisA. DuellR. ElderJ.B. HiltyJ. KumarB. LangJ. LehmanN.L. MandtR. NguyenP. PilarskiR. RaiK. SchoenfieldL. SenecalK. WakelyP. HansenP. LechanR. PowersJ. TischlerA. GrizzleW.E. SextonK.C. KastlA. HendersonJ. PortenS. WaldmannJ. FassnachtM. AsaS.L. SchadendorfD. CouceM. GraefenM. HulandH. SauterG. SchlommT. SimonR. TennstedtP. OlabodeO. NelsonM. BatheO. CarrollP.R. ChanJ.M. DisaiaP. GlennP. KelleyR.K. LandenC.N. PhillipsJ. PradosM. SimkoJ. Smith-McCuneK. VandenBergS. RogginK. FehrenbachA. KendlerA. SifriS. SteeleR. JimenoA. CareyF. ForgieI. MannelliM. CarneyM. HernandezB. CamposB. Herold-MendeC. JungkC. UnterbergA. von DeimlingA. BosslerA. GalbraithJ. JacobusL. KnudsonM. KnutsonT. MaD. MilhemM. SigmundR. GodwinA.K. MadanR. RosenthalH.G. AdebamowoC. AdebamowoS.N. BoussioutasA. BeerD. GiordanoT. Mes-MassonA-M. SaadF. BocklageT. LandrumL. MannelR. MooreK. MoxleyK. PostierR. WalkerJ. ZunaR. FeldmanM. ValdiviesoF. DhirR. LuketichJ. Mora PineroE.M. Quintero-AguiloM. CarlottiC.G. Dos SantosJ.S. KempR. SankarankutyA. TirapelliD. CattoJ. AgnewK. SwisherE. CreaneyJ. RobinsonB. ShelleyC.S. GodwinE.M. KendallS. ShipmanC. BradfordC. CareyT. HaddadA. MoyerJ. PetersonL. PrinceM. RozekL. WolfG. BowmanR. FongK.M. YangI. KorstR. RathmellW.K. Fantacone-CampbellJ.L. HookeJ.A. KovatichA.J. ShriverC.D. DiPersioJ. DrakeB. GovindanR. HeathS. LeyT. Van TineB. WesterveltP. RubinM.A. LeeJ.I. AredesN.D. MariamidzeA. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics.Cell20181732400416.e1110.1016/j.cell.2018.02.05229625055
     [Google Scholar]
  28. GuoR. DaiH. LiuF. LiuM. LiX. LiT. LiaoJ. ChenZ.S. LiuY. FangS. The prognostic and drug-targeting value of lymphoid enhancer-binding factor-1 in hepatocellular carcinoma.Rec. Pat. Anticancer Drug Discov.202318221122310.2174/157489281766622083112222636045537
     [Google Scholar]
  29. CaiH. ChenS. WuZ. WangF. TangS. LiD. WangD. GuoW. Comprehensive analysis of ZNF692 as a potential biomarker associated with immune infiltration in a pan cancer analysis and validation in hepatocellular carcinoma.Aging (Albany NY)20231522130411305810.18632/aging.20521837980166
     [Google Scholar]
  30. ZhouF. LinQ. ZhengZ. Cytokine-like protein 1 (CYTL1) as a key target of M-stage immune infiltration in stomach adenocarcinoma.BioMed Res. Int.202320231292621810.1155/2023/292621836825034
     [Google Scholar]
  31. LoveM.I. HuberW. AndersS. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.Genome Biol.2014151255010.1186/s13059‑014‑0550‑825516281
     [Google Scholar]
  32. YeX. AnL. WangX. ZhangC. HuangW. SunC. LiR. MaH. WangH. GaoM. ALOX5AP predicts poor prognosis by enhancing M2 macrophages polarization and immunosuppression in serous ovarian cancer microenvironment.Front. Oncol.20211167510410.3389/fonc.2021.67510434094977
     [Google Scholar]
  33. YuG. WangL.G. HanY. HeQ.Y. ClusterProfiler: An R package for comparing biological themes among gene clusters.OMICS201216528428710.1089/omi.2011.011822455463
     [Google Scholar]
  34. SubramanianA. TamayoP. MoothaV.K. MukherjeeS. EbertB.L. GilletteM.A. PaulovichA. PomeroyS.L. GolubT.R. LanderE.S. MesirovJ.P. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles.Proc. Natl. Acad. Sci. USA200510243155451555010.1073/pnas.050658010216199517
     [Google Scholar]
  35. ChenT. ZhuC. WangX. PanY. LncRNA ELF3-AS1 is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma.Can. J. Gastroenterol. Hepatol.2021202111210.1155/2021/832348734336727
     [Google Scholar]
  36. HänzelmannS. CasteloR. GuinneyJ. GSVA: gene set variation analysis for microarray and RNA-Seq data.BMC Bioinformatics2013141710.1186/1471‑2105‑14‑723323831
     [Google Scholar]
  37. BindeaG. MlecnikB. TosoliniM. KirilovskyA. WaldnerM. ObenaufA.C. AngellH. FredriksenT. LafontaineL. BergerA. BrunevalP. FridmanW.H. BeckerC. PagèsF. SpeicherM.R. TrajanoskiZ. GalonJ. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.Immunity201339478279510.1016/j.immuni.2013.10.00324138885
     [Google Scholar]
  38. YoshiharaK. ShahmoradgoliM. MartínezE. VegesnaR. KimH. Torres-GarciaW. TreviñoV. ShenH. LairdP.W. LevineD.A. CarterS.L. GetzG. Stemke-HaleK. MillsG.B. VerhaakR.G.W. Inferring tumour purity and stromal and immune cell admixture from expression data.Nat. Commun.201341261210.1038/ncomms361224113773
     [Google Scholar]
  39. QuintanilhaJ.C.F. StorandtM.H. GrafR.P. LiG. KellerR. LinD.I. RossJ.S. HuangR.S.P. SchrockA.B. OxnardG.R. ChakrabartiS. MahipalA. Tumor mutational burden in real-world patients with pancreatic cancer: Genomic alterations and predictive value for immune checkpoint inhibitor effectiveness.JCO Precis. Oncol.202377e230009210.1200/PO.23.0009237410975
     [Google Scholar]
  40. ChakrabartiS. BucheitL. StarrJ.S. Innis-SheltonR. ShergillA. DadaH. RestaR. WagnerS. FeiN. KasiP.M. Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer.J. Immunother. Cancer2022106e00448510.1136/jitc‑2021‑00448535710297
     [Google Scholar]
  41. ZhengH. LongG. ZhengY. YangX. CaiW. HeS. QinX. LiaoH. Glycolysis-related SLC2A1 is a potential pan-cancer biomarker for prognosis and immunotherapy.Cancers (Basel)20221421534410.3390/cancers1421534436358765
     [Google Scholar]
  42. BonnevilleR. KrookM.A. KauttoE.A. MiyaJ. WingM.R. ChenH.Z. Landscape of microsatellite instability across 39 cancer types.JCO Precis. Oncol.20172017PO.17.0007310.1200/PO.17.00073
     [Google Scholar]
  43. ZhongF. LiuJ. GaoC. ChenT. LiB. Downstream regulatory network of MYBL2 mediating its oncogenic role in melanoma.Front. Oncol.20221281607010.3389/fonc.2022.81607035664780
     [Google Scholar]
  44. WangZ. WangK. YuX. ChenM. DuY. Comprehensive analysis of expression signature and immune microenvironment signature of biomarker Endothelin Receptor Type A in stomach adenocarcinoma.J. Cancer20221372086210410.7150/jca.6867335517422
     [Google Scholar]
  45. ZhengD. LongS. XiM. Identification of TRPM2 as a potential therapeutic target associated with immune infiltration: A comprehensive pan-cancer analysis and experimental verification in ovarian cancer.Int. J. Mol. Sci.202324151191210.3390/ijms24151191237569287
     [Google Scholar]
  46. ChenB. DingX. WanA. QiX. LinX. WangH. MuW. WangG. ZhengJ. Comprehensive analysis of TLX2 in pan cancer as a prognostic and immunologic biomarker and validation in ovarian cancer.Sci. Rep.20231311624410.1038/s41598‑023‑42171‑537758722
     [Google Scholar]
  47. RuiX. XuY. HuangY. JiL. JiangX. lncRNA DLG1-AS1 promotes cell proliferation by competitively binding with miR-107 and up-regulating ZHX1 expression in cervical cancer.Cell Physiol. Biochem.20184951792180310.1159/000493625
     [Google Scholar]
  48. DengY. LiuL. FengW. LinZ. NingY. LuoX. High expression of MYL9 indicates poor clinical prognosis of epithelial ovarian cancer.Rec. Pat. Anticancer Drug Discov.202116453353910.2174/1574891X1666621070615374034551701
     [Google Scholar]
  49. LiuL. HuK. ZengZ. XuC. LvJ. LinZ. WenB. Expression and clinical significance of microtubule-actin cross-linking factor 1 in serous ovarian cancer.Rec. Pat. Anticancer Drug Discov.2021161667210.2174/157489281666621021109154333573562
     [Google Scholar]
  50. ZhuangJ. TuX. CaoK. GuoS. MaoX. PanJ. The expression and role of tyrosine kinase ETK/BMX in renal cell carcinoma. Journal of experimental & clinical cancer research.CR (East Lansing Mich.)201433125
     [Google Scholar]
  51. LuX. LiG. LiuS. WangH. ZhangZ. ChenB. Bioinformatics analysis of KIF1A expression and gene regulation network in ovarian carcinoma.Int. J. Gen. Med.2021143707371710.2147/IJGM.S32359134321916
     [Google Scholar]
  52. KričkovićE. NovkovićI. LukicT. KričkovićZ. Using DPSEEA framework to investigate the relation between arsenic concentration values in waters and cancer rates in AP vojvodina (North Serbia).Pol. J. Environ. Stud.2022202231
     [Google Scholar]
  53. ZhuY. ZhengD. LeiL. CaiK. XieH. ZhengJ. YuC. High expression of syndecan-4 is related to clinicopathological features and poor prognosis of pancreatic adenocarcinoma.BMC Cancer2022221104210.1186/s12885‑022‑10128‑y36199068
     [Google Scholar]
  54. XieJ. PengY. ChenX. LiQ. JianB. WenZ. LiuS. LACTB mRNA expression is increased in pancreatic adenocarcinoma and high expression indicates a poor prognosis.PLoS One2021161e024590810.1371/journal.pone.024590833507917
     [Google Scholar]
  55. KuangW. WangX. DingJ. LiJ. JiM. ChenW. WangL. YangP. PTPN2, a key predictor of prognosis for pancreatic adenocarcinoma, significantly regulates cell cycles, apoptosis, and metastasis.Front. Immunol.20221380531110.3389/fimmu.2022.80531135154122
     [Google Scholar]
  56. YouW. KeJ. ChenY. CaiZ. HuangZ. HuP. WuX. SQLE, A key enzyme in cholesterol metabolism, correlates with tumor immune infiltration and immunotherapy outcome of pancreatic adenocarcinoma.Front. Immunol.20221386424410.3389/fimmu.2022.86424435720314
     [Google Scholar]
  57. PulawskaK. Ponikwicka-TyszkoD. LebiedzinskaW. GuoP. BernaczykP. Pilaszewicz-PuzaA. LiX. ChruscielM. LupuO. LeskinenS. MakelaJ.A. ToppariJ. WolczynskiS. Coelingh BenninkH.J.T. HuhtaniemiI. RahmanN.A. Novel expression of zona pellucida 3 protein in normal testis; Potential functional implications.Mol. Cell. Endocrinol.202253911150210.1016/j.mce.2021.11150234736966
     [Google Scholar]
  58. JolyY. SaulnierK.M. OsienG. KnoppersB.M. The ethical framing of personalized medicine.Curr. Opin. Allergy Clin. Immunol.201414540440810.1097/ACI.000000000000009125054830
     [Google Scholar]
  59. SalariP. LarijaniB. Ethical issues surrounding personalized medicine: A literature review.Acta Med. Iran.201755320921728282721
     [Google Scholar]
  60. HinschE. AiresV.A. HedrichF. OehningerS. HinschK.D. A synthetic decapeptide from a conserved ZP3 protein domain induces the G protein-regulated acrosome reaction in bovine spermatozoa.Theriogenology20056361682169410.1016/j.theriogenology.2004.07.02515763111
     [Google Scholar]
  61. PiergentiliR. BasileG. NocellaC. CarnevaleR. MarinelliE. PatroneR. ZaamiS. Using ncRNAs as tools in cancer diagnosis and treatment - The way towards personalized medicine to improve patients’ health.Int. J. Mol. Sci.20222316935310.3390/ijms2316935336012617
     [Google Scholar]
  62. KoleckovaM. JanikovaM. KolarZ. MicroRNAs in triple-negative breast cancer.Neoplasma201865111310.4149/neo_2018_170115N3629322783
     [Google Scholar]
  63. CavaliereA.F. PerelliF. ZaamiS. PiergentiliR. MatteiA. VizzielliG. ScambiaG. StrafaceG. RestainoS. SignoreF. Towards personalized medicine: Non-coding RNAs and endometrial cancer.Healthcare (Basel)20219896510.3390/healthcare908096534442102
     [Google Scholar]
  64. Dias CostaA. VäyrynenS.A. ChawlaA. ZhangJ. VäyrynenJ.P. LauM.C. WilliamsH.L. YuanC. Morales-OyarvideV. ElganainyD. SinghH. ClearyJ.M. PerezK. NgK. Freed-PastorW. ManciasJ.D. DouganS.K. WangJ. RubinsonD.A. DunneR.F. KozakM.M. BraisL. ReillyE. ClancyT. LinehanD.C. ChangD.T. HezelA.F. KoongA.C. AguirreA.J. WolpinB.M. NowakJ.A. Neoadjuvant chemotherapy is associated with altered immune cell infiltration and an anti-tumorigenic microenvironment in resected pancreatic cancer.Clin. Cancer Res.202228235167517910.1158/1078‑0432.CCR‑22‑112536129461
     [Google Scholar]
  65. ThyagarajanA. AlshehriM.S.A. MillerK.L.R. SherwinC.M. TraversJ.B. SahuR.P. Myeloid-derived suppressor cells and pancreatic cancer: Implications in novel therapeutic approaches.Cancers (Basel)20191111162710.3390/cancers1111162731652904
     [Google Scholar]
  66. MahajanU.M. LanghoffE. GoniE. CostelloE. GreenhalfW. HalloranC. OrmannsS. KrugerS. BoeckS. RibbackS. BeyerG. DombroswkiF. WeissF.U. NeoptolemosJ.P. WernerJ. D’HaeseJ.G. BazhinA. PeterhanslJ. PichlmeierS. BüchlerM.W. KleeffJ. GanehP. SendlerM. PalmerD.H. KohlmannT. RadR. RegelI. LerchM.M. MayerleJ. Immune cell and stromal signature associated with progression-free survival of patients with resected pancreatic ductal adenocarcinoma.Gastroenterology2018155516251639.e210.1053/j.gastro.2018.08.00930092175
     [Google Scholar]
  67. FarkonaS. DiamandisE.P. BlasutigI.M. Cancer immunotherapy: The beginning of the end of cancer?BMC Med.20161417310.1186/s12916‑016‑0623‑527151159
     [Google Scholar]
  68. RizzoA. DadduzioV. RicciA.D. MassariF. Di FedericoA. Gadaleta-CaldarolaG. BrandiG. Lenvatinib plus pembrolizumab: The next frontier for the treatment of hepatocellular carcinoma?Expert Opin. Investig. Drugs202231437137810.1080/13543784.2021.194853234167433
     [Google Scholar]
  69. RizzoA. BrandiG. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.Cancer Treat. Res. Commun.20212710032810.1016/j.ctarc.2021.10032833549983
     [Google Scholar]
  70. RizzoA. RicciA.D. BrandiG. Recent advances of immunotherapy for biliary tract cancer.Expert Rev. Gastroenterol. Hepatol.202115552753610.1080/17474124.2021.185352733215952
     [Google Scholar]
  71. MunroM.J. WickremesekeraS.K. PengL. TanS.T. ItinteangT. Cancer stem cells in colorectal cancer: A review.J. Clin. Pathol.201871211011610.1136/jclinpath‑2017‑20473928942428
     [Google Scholar]
  72. WangL. LiuW. LiuJ. WangY. TaiJ. YinX. TanJ. Identification of immune-related therapeutically relevant biomarkers in breast cancer and breast cancer stem cells by transcriptome-wide analysis: A clinical prospective study.Front. Oncol.20211055413810.3389/fonc.2020.55413833718103
     [Google Scholar]
  73. RamaswamiR. BayerR. GaleaS. Precision medicine from a public health perspective.Annu. Rev. Public Health202439115316810.1146/annurev‑publhealth‑040617‑01415829166244
     [Google Scholar]
/content/journals/ppl/10.2174/0109298665350171241204153202
Loading
ZP3 Expression in Pancreatic Adenocarcinoma: Its Implications for the Prognosis and Therapy
PPL 32, 124 (2025); https://doi.org/10.2174/0109298665350171241204153202
/content/journals/ppl/10.2174/0109298665350171241204153202
/content/journals/ppl/10.2174/0109298665350171241204153202
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): drug sensitivity; immune infiltration; Pancreatic adenocarcinoma; prognosis; TMB/MSI; ZP3

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test